Boardroom Alpha
Meeting calendar
IRLA · Special meeting · Tuesday, October 6, 2026

Irulya Therapeutics Inc

6 nominees · 6 ballot items.

Stockholders are asked to approve Nasdaq-related issuances tied to the Orphai acquisition and private placement, increase authorized common stock, adopt new equity compensation and employee stock purchase plans, and authorize adjournment to solicit votes.

Market cap
$405M
1Y TSR
-91.4%
Board grade
C
Record date
Aug 24, 2026
Filing
DEF 14A
Meeting concluded · Oct 6, 2026

Follow how the vote landed and what changed on Irulya Therapeutics Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.

Proposals

On the ballot6

  1. 1

    Approval of issuance of common stock upon conversion of Series C Preferred Stock and exercise of Warrants and Orphai Options

    ManagementBoard: FOR

    Approve the issuance of common stock upon conversion of Series C Preferred Stock and exercise of the Warrants and Orphai Options, which would exceed 20% of outstanding shares under Nasdaq Listing Rule 5635(a) and may, together with management and Board changes, constitute a Nasdaq change of control under Rule 5635(b).

    More detail

    Proposal No. 1 seeks approval for the issuance of common stock underlying Series C Preferred Stock, Warrants, and Orphai Options issued or assumed in connection with the completed Orphai acquisition and related financing. Without beneficial-ownership limitations, the securities could result in the issuance of approximately 16.6 million shares, or about 94.23% of the common stock outstanding as of the record date. Nasdaq Rule 5635(a) requires stockholder approval when an acquisition-related issuance exceeds 20% of outstanding shares. Nasdaq Rule 5635(b) may also require approval where the issuance, together with management and Board changes, could produce a Nasdaq-defined change of control. The Company has already completed the acquisition and is not asking stockholders to approve the Merger Agreement itself. If approved, Series C Preferred Stock will automatically convert, Warrants will become exercisable for common stock or convertible preferred stock, and Orphai Options will become exercisable, subject to applicable beneficial-ownership limitations. Approval is also tied to planned leadership changes, including Brigette Roberts becoming CEO, John Militello becoming CFO, Keith Fandrick becoming COO, and a reduction in Board size. Failure to approve could delay conversion and exercise, require repeated solicitation efforts, and expose the Company to potentially material cash-settlement obligations to preferred holders. The Board unanimously recommends voting FOR because approval is necessary for Nasdaq compliance and to implement the post-acquisition capitalization and operating structure.

  2. 2

    Approval of issuance of common stock upon conversion of PIPE Preferred Shares and exercise of PIPE Warrants

    ManagementBoard: FOR

    Approve the issuance of common stock upon conversion of the PIPE Preferred Shares and exercise of the PIPE Warrants at potentially less than Nasdaq’s Minimum Price under Listing Rule 5635(d).

    More detail

    Proposal No. 2 seeks approval for common stock issuable upon conversion of the PIPE Preferred Shares and exercise of the PIPE Warrants sold in the May 2026 private placement. The financing generated approximately $115 million in upfront proceeds and could provide up to approximately $72 million more upon warrant exercise. The PIPE securities represent approximately 11.25 million potential common shares without applying beneficial-ownership limitations. Nasdaq Rule 5635(d) requires approval when a non-public offering may result in issuance of at least 20% of outstanding shares at a price below the applicable Minimum Price. The deemed conversion price was approximately $15.3365, below the relevant May 2026 Nasdaq closing and five-day average prices of $23.00 and $24.20. Approval would permit conversion and exercise, subject to ownership blockers and the warrant’s event-based exercise window tied to LAM-001 trial news. Existing stockholders would not lose their current shares but would experience substantial economic and voting dilution. Failure to approve would delay the securities’ common-stock conversion or exercise, require continued solicitation at later meetings, and could create significant cash-settlement exposure. The Board recommends FOR because the vote is required for Nasdaq compliance and to unlock the financing securities.

  3. 3

    Amendment to certificate of incorporation to increase authorized common stock

    ManagementBoard: FOR

    Approve an amendment increasing authorized common stock from 250,000,000 to 275,000,000 shares, while leaving authorized preferred stock unchanged.

    More detail

    Proposal No. 3 asks stockholders to amend the charter to increase authorized common stock by 25 million shares, from 250 million to 275 million. The amendment would not increase authorized preferred stock, including Series C Preferred Stock. The Company states that the new shares would have the same rights as existing common stock. Management identifies potential uses including financings, acquisitions, warrant and convertible-security issuances, equity compensation, stock dividends, stock splits, recapitalizations, and other proper corporate purposes. The Company currently says it has sufficient authorized shares for the expected Series C conversion and warrant exercises if Proposals 1 and 2 pass. Future issuances generally could occur without further stockholder approval unless required by law, regulation, or Nasdaq rules. The proposal carries dilution risks to earnings per share, voting power, and existing equity interests, and the authorized but unissued shares could also make a takeover more difficult. The Board states that the increase is not proposed in response to a specific takeover threat, although it acknowledges possible anti-takeover effects. Approval would cause the Company to file a Delaware certificate amendment, and the Board recommends FOR to preserve financing and corporate flexibility.

  4. 4

    Approval of the 2026 Equity Incentive Plan

    ManagementBoard: FOR

    Approve the 2026 Equity Incentive Plan, which replaces prior equity plans, authorizes new shares and returning shares for awards, and permits options, restricted stock, RSUs, SARs, performance awards, and other equity awards.

    More detail

    Proposal No. 4 asks stockholders to approve the 2026 Equity Incentive Plan, which would become effective immediately upon approval. The plan would succeed and consolidate several legacy Quince and Orphai equity plans, while ending new grants under those predecessor plans. It authorizes incentive and nonstatutory stock options, stock appreciation rights, restricted stock, RSUs, performance awards, and other stock-based awards for employees, directors, and consultants. The initial reserve is 821,872 shares, supplemented by up to 1,377,845 returning shares from prior awards and annual increases of up to 5% of specified outstanding shares through 2036. The plan includes a 7 million-share ISO sublimit and a $750,000 annual compensation cap for non-employee directors, increased to $1 million in a director’s first year. Management argues that equity compensation is important for recruitment, retention, motivation, and alignment, while acknowledging dilution and emphasizing burn-rate management. The administrator would have broad discretion over award terms, performance metrics, vesting, and certain repricing actions with participant consent where required. The plan includes corporate-transaction treatment, clawback provisions, tax withholding mechanisms, and Delaware-law governance. The Board recommends FOR because it believes the plan is necessary to maintain a competitive compensation program and support the combined Company’s workforce.

  5. 5

    Approval of the 2026 Employee Stock Purchase Plan

    ManagementBoard: FOR

    Approve the 2026 ESPP, including qualified and non-qualified components allowing eligible employees to purchase common stock, generally at a discount through payroll deductions.

    More detail

    Proposal No. 5 asks stockholders to approve the 2026 Employee Stock Purchase Plan, which would become effective immediately if approved. The plan has a Section 423 component intended to receive favorable U.S. tax treatment and a non-423 component designed to accommodate foreign employees and applicable local-law requirements. Eligible employees may contribute through payroll deductions, generally up to 15% of earnings, to purchase common stock at no less than the lesser of 85% of the offering-date or purchase-date fair market value. The initial share reserve is 142,045 shares, with potential annual increases through 2036 capped by the lesser of 1% of specified outstanding shares or 284,090 shares. The plan incorporates statutory eligibility restrictions, including the 5% ownership limit and the $25,000 annual purchase-right limitation for the Section 423 component. The Board or a committee would administer offerings, establish purchase periods, designate participating affiliates, and adopt procedures for non-U.S. participation. The plan also provides for adjustments upon capitalization changes and treatment of purchase rights in corporate transactions. Management’s stated purpose is to attract and retain employees and provide incentives aligned with Company success. The Board recommends FOR because it views employee stock purchasing as a useful compensation and retention tool.

  6. 6

    Adjournment or postponement of the Special Meeting to solicit votes for Proposals 1, 2 and/or 3

    ManagementBoard: FOR

    Approve adjournment or postponement of the Special Meeting, if necessary, so management can continue soliciting votes for the Nasdaq issuance and authorized-share proposals.

    More detail

    Proposal No. 6 seeks authority to adjourn, postpone, or continue the Special Meeting if votes supporting Proposals 1, 2, or 3 are insufficient. The additional time would allow management to solicit proxies, including from stockholders who previously voted against those proposals. If approved, the proxy holders could adjourn the meeting or any later adjourned session for further solicitation. If not approved, the meeting would not be adjourned under this authority, although the Company remains obligated to continue seeking approval of the Required Company Stockholder Matters at later meetings. The proposal is especially relevant because Proposals 1 through 3 are interdependent transaction and capitalization matters tied to Nasdaq compliance. The Company warns that repeated meetings would impose legal and solicitation costs and divert management attention. Approval requires a majority of the voting power present or represented and voted for or against the proposal. Abstentions and broker non-votes have no effect under the stated voting rules. Management views the adjournment mechanism as a procedural safeguard to maximize the opportunity to obtain the required votes. The Board recommends FOR to preserve flexibility to continue solicitation if the initial meeting does not produce sufficient support.

Director elections

Nominees on the ballot6

Independent
Tenure on this board
4.3 yrs
Ownership

Top institutional holders10

Latest 13F quarter
1Ikarian Capital, LLC7.1%72,251$1M
2MILLENNIUM MANAGEMENT LLC7.0%70,779$1M
3BALYASNY ASSET MANAGEMENT L.P.6.9%69,967$13M
4Squadron Capital Management LLC4.0%40,375$734K
5Shay Capital LLC1.7%17,468$329K
6BOOTHBAY FUND MANAGEMENT, LLC1.4%13,911$253K
7VANGUARD CAPITAL MANAGEMENT LLC1.2%12,044$219K
8JANE STREET GROUP, LLC0.7%7,133$130K
9JANE STREET GROUP, LLC0.5%5,509$100K
10Cormorant Asset Management, LP0.5%5,498$100K
Filings

Irulya Therapeutics Inc proxy statements and SEC reports

Annual & quarterly reports (10-K, 10-Q)
Proxy statements (DEF 14A)
Reference

Frequently asked questions

When is the Irulya Therapeutics Inc 2026 special meeting?
Irulya Therapeutics Inc (IRLA) holds its 2026 special shareholder meeting on Tuesday, October 6, 2026.
What is the record date for the Irulya Therapeutics Inc 2026 meeting?
The record date for the Irulya Therapeutics Inc 2026 meeting is Monday, August 24, 2026. Shareholders of record on or before that date are eligible to vote.
Who are the director nominees for Irulya Therapeutics Inc's 2026 meeting?
The board is presenting 6 director nominees at the Irulya Therapeutics Inc 2026 meeting, listed with their independence status and background.
What proposals will shareholders vote on at the Irulya Therapeutics Inc 2026 meeting?
Shareholders will vote on 6 proposals at the Irulya Therapeutics Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer